In TRANSCEND CLL 004, CD19-directed CART monotherapy achieved an 82% ORR (45% CR), with peripheral blood and bone marrow uMRD rates of 75% and 65%, respectively. The gene discussed is CD19; the disease is B-cell chronic lymphocytic leukemia.